|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We identified the haplotype S2/C with a significant increased risk (P < 0.001) to coronary artery disease with increased levels of circulating triglycerides compared to other haplotypes in patients.
|
19701693 |
2010 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Common variants associated with plasma triglycerides and risk for coronary artery disease.
|
24097064 |
2013 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The -1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study.
|
16682041 |
2007 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A rare variant in APOC3(rs138326449) has been associated with triglyceride, very low-density lipoprotein, and high-density lipoprotein levels, as well as risk of coronary heart disease.
|
27114411 |
2016 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study.
|
11500189 |
2001 |
|
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease.
|
31329855 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, VLDL particles with apoC-III may play a central role in identifying the high risk of coronary heart disease in hypertriglyceridemia, but their substantial prevalence in normolipidemics may be of clinical significance as well.
|
11483625 |
2001 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These impactful mouse studies were supported by the initial finding that APOC3 predicted coronary artery disease events in participants of the prospective Coronary Artery Calcification in Type 1 Diabetes study with normal TG levels.
|
31449060 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
APOA5 -1131T>C and APOC3 -455T>C polymorphisms are associated with an increased risk of coronary heart disease.
|
26782469 |
2015 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Synergistic effect between lipoprotein lipase and apolipoprotein C3 genes in determining the severity of coronary artery disease.
|
23377670 |
2013 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population.
|
25380998 |
2014 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In humans, loss-of-function mutations in APOC3 are associated with reduced plasma TG levels and reduced risk for ischemic vascular disease and coronary heart disease.
|
26435212 |
2015 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts.
|
29162611 |
2018 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease: a case-control and meta-analysis study.
|
26387083 |
2015 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association between apolipoprotein C3 Sst I, T-455C, C-482T and C1100T polymorphisms and risk of coronary heart disease.
|
24430880 |
2014 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein C-III (apoC-III), a small proinflammatory protein present on 6% to 7% of high-density lipoprotein (HDL) particles, defines a subspecies of HDL adversely associated with coronary heart disease in primarily white cohorts.
|
29540426 |
2018 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A rare variant in APOC3(rs138326449) has been associated with triglyceride, very low-density lipoprotein, and high-density lipoprotein levels, as well as risk of coronary heart disease.
|
27114411 |
2016 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, VLDL particles with apoC-III may play a central role in identifying the high risk of coronary heart disease in hypertriglyceridemia, but their substantial prevalence in normolipidemics may be of clinical significance as well.
|
11483625 |
2001 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Different genotypes, i.e., APOA5 and APOC3 variants, may lead to similar biochemical phenotypes, namely hypertriglyceridemia, but to contrasting clinical phenotypes such as the presence of angiographically proven CAD.
|
16682041 |
2007 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association of -1131T>C with CAD risk, however, was independent of apoA-V levels and likely acts through linkage disequilibrium with APOC3 variants.
|
16769999 |
2006 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Heterozygous deficiency of APOC3 has been shown to protect against coronary heart disease; we identified APOC3 homozygous pLoF carriers in our cohort.
|
28406212 |
2017 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MS patients with CAD had significantly higher apoC-III levels than did CAD-free MS patients.
|
14563827 |
2003 |
|
Coronary Artery Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
ApoC-III gene polymorphisms and risk of coronary artery disease.
|
12235176 |
2002 |
|
Coronary Artery Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Only ApoC-III remained associated with FVIIa-AT plasma concentration, even after adjustment for sex, age, CAD diagnosis, body mass index, renal function, smoking status, lipid-lowering therapies and FVIIa levels.
|
30602199 |
2019 |
|
Coronary Artery Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It is effective in decreasing triglycerides by targeting apoC3 levels in patients with coronary heart disease.
|
30511426 |
2019 |